Overview

TAX + Carboplatin or Cisplatin 1st Line Post-Surgery Ovarian

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Evaluate response rate of Docetaxel in combination with Carboplatin or Cisplatin as first line chemotherapy in epithelial ovarian cancer. Assess the progression free survival, tolerance, duration of response and survival in the same patient population.
Phase:
Phase 2
Details
Lead Sponsor:
Sanofi
Treatments:
Docetaxel